Skip to main content

Table 1 Baseline characteristics of study cases with febuxostat and allopurinol

From: Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study

Characteristics Acute renal failure with febuxostat as the suspected drug (n = 317) Acute renal failure with allopurinol as the suspected drug (n = 1008)
Age, years, mean (SD) 68.0 (15.0) 67.0 (14.5)
Age, n (%)
 19–44 27 (8.5) 79 (7.8)
 45–64 83 (26.2) 306 (30.4)
 65–74 81 (25.6) 270 (26.8)
 ≥ 75 126 (39.7) 353 (35.0)
Sex, n (%)
 Male 172 (54.3) 577 (57.2)
 Female 145 (45.7) 431 (42.8)
Reporter qualification, n (%)
 Healthcare professional 281 (88.6) 863 (85.6)
 Not a healthcare professional 17 (5.4) 41 (4.1)
 Unknown 19 (6.0) 104 (10.3)
 The only suspected drug, n (%) 184 (58.0) 447 (44.3)
Continent, n (%)
 North America 115 (36.3) 233 (23.1)
 Europe 115 (36.3) 489 (48.5)
 Asia 82 (25.9) 237 (23.5)
 Other regions* 5 (1.6) 49 (4.9)
Seriousness of ARF
 Death 22 (6.9) 97 (9.6)
 Life-threatening event 32 (10.1) 111 (11.0)
 Disability/incapacity 18 (5.7) 13 (1.3)
 Hospitalization (caused or prolonged) 115 (36.3) 482 (47.8)
 Others 70 (22.1) 111 (11.0)
 Unknown 60 (18.9) 194 (19.2)
  1. *Included Oceania and Africa